(Q39718845)

14 September 2017

0 references

Early treatment with eculizumab in atypical haemolytic uraemic syndrome (English)

1 reference

14 September 2017

Maria Garjau

1

1 reference

14 September 2017

María Azancot

2

1 reference

14 September 2017

Rosa Ramos

3

1 reference

14 September 2017

Pilar Sánchez-Corral

4

1 reference

14 September 2017

Maria Angeles Montero

5

1 reference

14 September 2017

Daniel Serón

6

1 reference

14 September 2017

language of work or name

1 reference

31 January 2012

1 reference

Clinical kidney journal / an academic journal of the ERA-EDTA (European Renal Association - European Dialysis and Transplant Association)

14 September 2017

1 reference

14 September 2017

5

1 reference

14 September 2017

1

1 reference

14 September 2017

31-33

1 reference

Creative Commons Attribution-NonCommercial 4.0 International

14 September 2017

start time

2 October 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4400458

Atypical hemolytic-uremic syndrome

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4400458

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4400458

Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4400458

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4400458

Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4400458

Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4400458

Atypical hemolytic uremic syndrome: update on the complement system and what is new.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4400458

Eculizumab for congenital atypical hemolytic-uremic syndrome.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4400458

Eculizumab for Atypical Hemolytic–Uremic Syndrome

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4400458

2 December 2018

Identifiers

DOI

10.1093/NDTPLUS/SFR157

1 reference

14 September 2017

1 reference

14 September 2017

PubMed publication ID

26069743

1 reference